Published in Biol Psychiatry on July 01, 1990
The Impact of Caffeine on Cognition in Schizophrenia | NCT02832401
Caffeine-induced synaptic potentiation in hippocampal CA2 neurons. Nat Neurosci (2011) 1.62
Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders. Curr Pharm Des (2008) 1.13
Higher serum caffeine in smokers with schizophrenia compared to smoking controls. Drug Alcohol Depend (2010) 0.87
Systemic administration of the adenosine A(2A) agonist CGS 21680 induces sedation at doses that suppress lever pressing and food intake. Pharmacol Biochem Behav (2008) 0.86
From real-world events to psychosis: the emerging neuropharmacology of delusions. Schizophr Bull (2009) 0.84
Adenosine A(2A) receptors in psychopharmacology: modulators of behavior, mood and cognition. Curr Neuropharmacol (2009) 0.83
Association studies of the adenosine A2a receptor (1976T > C) genetic polymorphism in Parkinson's disease and schizophrenia. J Neural Transm (Vienna) (2005) 0.80
Reduced striatal ecto-nucleotidase activity in schizophrenia patients supports the "adenosine hypothesis". Purinergic Signal (2013) 0.78
Sensorimotor gating is disrupted by acute but not chronic systemic exposure to caffeine in mice. Psychopharmacology (Berl) (2014) 0.77
Novel Therapeutic GPCRs for Psychiatric Disorders. Int J Mol Sci (2015) 0.77
Schizophrenia: Nutrition and Alternative Treatment Approaches. Schizophr Bull (2015) 0.76
"Clozapine makes me quite drowsy, so when I wake up in the morning those first cups of coffee are really handy": an exploratory qualitative study of excessive caffeine consumption among individuals with schizophrenia. BMC Psychiatry (2014) 0.76
Investigation into effects of antipsychotics on ectonucleotidase and adenosine deaminase in zebrafish brain. Fish Physiol Biochem (2015) 0.75
Effects of caffeine or RX821002 in rats with a neonatal ventral hippocampal lesion. Front Behav Neurosci (2014) 0.75
Upregulation of adenosine A2A receptors induced by atypical antipsychotics and its correlation with sensory gating in schizophrenia patients. Psychiatry Res (2012) 0.75
The Safety of Ingested Caffeine: A Comprehensive Review. Front Psychiatry (2017) 0.75
Anticipation of increasing monetary reward selectively recruits nucleus accumbens. J Neurosci (2001) 10.05
FMRI visualization of brain activity during a monetary incentive delay task. Neuroimage (2000) 5.15
Dissociation of reward anticipation and outcome with event-related fMRI. Neuroreport (2001) 4.99
National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Arch Gen Psychiatry (1991) 3.53
Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A (1997) 3.00
Cognitive effects of corticosteroids. Am J Psychiatry (1990) 2.85
A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity. Biol Psychiatry (2000) 2.32
Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology (2000) 2.28
Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology (1997) 2.20
A genetic determinant of the striatal dopamine response to alcohol in men. Mol Psychiatry (2010) 2.02
Apolipoprotein E epsilon 4 and clinical phenotype in schizophrenia. Lancet (1997) 2.02
Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatry (1991) 1.94
Cognitive substrates of thought disorder, I: the semantic system. Am J Psychiatry (1998) 1.90
NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology (1996) 1.88
Clinical and physiological consequences of rapid tryptophan depletion. Neuropsychopharmacology (2000) 1.86
Reduced benzodiazepine sensitivity in panic disorder. Arch Gen Psychiatry (1990) 1.84
Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry (1999) 1.79
Contrasts between patients with affective disorders and patients with schizophrenia on a neuropsychological test battery. Am J Psychiatry (1993) 1.78
The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry (1993) 1.75
Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol (1999) 1.67
Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry (1997) 1.64
Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry (1999) 1.63
Quantification of amphetamine-induced changes in [11C]raclopride binding with continuous infusion. J Cereb Blood Flow Metab (1997) 1.55
Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients. Preliminary results. Arch Gen Psychiatry (1988) 1.53
The suitability of [11C]-alpha-methyl-L-tryptophan as a tracer for serotonin synthesis: studies with dual administration of [11C] and [14C] labeled tracer. J Cereb Blood Flow Metab (2000) 1.48
Brain serotonin synthesis rates in rhesus monkeys determined by [11C]alpha-methyl-L-tryptophan and positron emission tomography compared to CSF 5-hydroxyindole-3-acetic acid concentrations. Neuropsychopharmacology (1998) 1.48
Is the mechanism of prefrontal hypofunction in depression the same as in schizophrenia? Regional cerebral blood flow during cognitive activation. Br J Psychiatry (1993) 1.47
Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol (1997) 1.46
Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications. N Engl J Med (1986) 1.45
A quantitative analysis of smooth pursuit eye tracking in monozygotic twins discordant for schizophrenia. Arch Gen Psychiatry (1997) 1.41
Suicidal behavior in chronic schizophrenic patients: a follow-up study. Can J Psychiatry (1986) 1.39
Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers. Biol Psychiatry (1998) 1.38
Effort and cognition in depression. Arch Gen Psychiatry (1982) 1.37
Prednisone effects on neurochemistry and behavior. Preliminary findings. Arch Gen Psychiatry (1990) 1.35
Neuropsychiatric effects of anabolic steroids in male normal volunteers. JAMA (1993) 1.34
The epidemiology of psychosis: the Suffolk County Mental Health Project. Schizophr Bull (1992) 1.34
Reduced central serotonin transporters in alcoholism. Am J Psychiatry (1998) 1.31
Large changes in Pluto's atmosphere as revealed by recent stellar occultations. Nature (2003) 1.28
High plasma norepinephrine levels in patients with major affective disorder. Am J Psychiatry (1982) 1.21
Dopamine D2 receptor density and personal detachment in healthy subjects. Am J Psychiatry (1998) 1.16
Rapid tryptophan depletion, sleep electroencephalogram, and mood in men with remitted depression on serotonin reuptake inhibitors. Arch Gen Psychiatry (1998) 1.15
Effects of acute tryptophan depletion on plasma and cerebrospinal fluid tryptophan and 5-hydroxyindoleacetic acid in normal volunteers. J Neurochem (1999) 1.15
The relationship between dorsolateral prefrontal neuronal N-acetylaspartate and evoked release of striatal dopamine in schizophrenia. Neuropsychopharmacology (2000) 1.14
No structural mutation in the dopamine D2 receptor gene in alcoholism or schizophrenia. Analysis using denaturing gradient gel electrophoresis. JAMA (1994) 1.12
Norepinephrine and its metabolites in cerebrospinal fluid, plasma, and urine. Relationship to hypothalamic-pituitary-adrenal axis function in depression. Arch Gen Psychiatry (1988) 1.08
Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biol Psychiatry (1997) 1.07
Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment. Arch Gen Psychiatry (1986) 1.06
Early parental loss and development of adult psychopathology. Arch Gen Psychiatry (1988) 1.06
Mechanism of peripheral noradrenergic stimulation by clozapine. Neuropsychopharmacology (1999) 1.04
The natural course of schizophrenia: a review of first-admission studies. Schizophr Bull (1992) 1.01
A functional serotonin transporter (5-HTT) polymorphism is associated with psychosis in neuroleptic-free schizophrenics. Mol Psychiatry (1998) 1.00
The effects of transdermal nicotine therapy for smoking cessation on depressive symptoms in patients with major depression. Neuropsychopharmacology (2001) 1.00
Controllable and uncontrollable stress in humans: alterations in mood and neuroendocrine and psychophysiological function. Am J Psychiatry (1987) 1.00
Autonomic neuropathy and painless myocardial infarction in diabetic patients. Histologic evidence of their relationship. Diabetes (1977) 1.00
Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse (1998) 0.99
Effects of acute metabolic stress on striatal dopamine release in healthy volunteers. Neuropsychopharmacology (2000) 0.99
A new algorithm for treating schizophrenia. Psychopharmacol Bull (1998) 0.99
Cerebrospinal fluid and behavioral changes after methyltestosterone administration: preliminary findings. Arch Gen Psychiatry (2001) 0.98
Neuroendocrine and behavioral effects of high-dose anabolic steroid administration in male normal volunteers. Psychoneuroendocrinology (2003) 0.98
In vivo association between alcohol intoxication, aggression, and serotonin transporter availability in nonhuman primates. Am J Psychiatry (1998) 0.98
Reduced CSF concentrations of homovanillic acid and homovanillic acid to 5-hydroxyindoleacetic acid ratios in depressed patients: relationship to suicidal behavior and dexamethasone nonsuppression. Am J Psychiatry (1986) 0.97
A pedigree of one family with delayed sleep phase syndrome. Chronobiol Int (2001) 0.97
Surgical stress in humans is accompanied by an increase in plasma beta-endorphin immunoreactivity. Life Sci (1981) 0.96
Blastomycosis. An important medical problem in the Central United States. JAMA (1966) 0.95
Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients. Science (1984) 0.95
Dysfunction in a prefrontal substrate of sustained attention in schizophrenia. Life Sci (1987) 0.95
Six-month stability of psychiatric diagnoses in first-admission patients with psychosis. Am J Psychiatry (1994) 0.93
Genome-wide linkage analysis of 972 bipolar pedigrees using single-nucleotide polymorphisms. Mol Psychiatry (2011) 0.93
Benzodiazepine withdrawal: overview and implications for the treatment of anxiety. Am J Med (1988) 0.93
Tyramine infusions and selective monoamine oxidase inhibitor treatment. I. Changes in pressor sensitivity. Psychopharmacology (Berl) (1981) 0.93
Physiological effects of high dose naloxone administration to normal adults. Life Sci (1982) 0.93
Quantitative neuroanatomy in schizophrenia. A controlled magnetic resonance imaging study. Arch Gen Psychiatry (1988) 0.93
The brain metabolic patterns of clozapine- and fluphenazine-treated patients with schizophrenia during a continuous performance task. Arch Gen Psychiatry (1997) 0.93
Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine. Am J Psychiatry (1996) 0.92
Disulfide bond assignment, lipid transfer activity and secondary structure of a 7-kDa plant lipid transfer protein, LTP2. Eur J Biochem (2001) 0.92
Endocrine effects of the cold pressor test: relationships to subjective pain appraisal and coping. Psychiatry Res (1984) 0.92
Childhood-onset schizophrenia: an NIMH study in progress. Schizophr Bull (1994) 0.92
Linkage disequilibrium mapping at DAT1, DRD5 and DBH narrows the search for ADHD susceptibility alleles at these loci. Mol Psychiatry (2003) 0.92
Neuropharmacological antagonism of the beta-carboline-induced "anxiety" response in rhesus monkeys. J Neurosci (1985) 0.92
Plasma norepinephrine level in affective disorders. Relationship to melancholia. Arch Gen Psychiatry (1985) 0.92
Atrophy limited to the third ventricle in chronic schizophrenic patients. Report of a controlled series. Arch Gen Psychiatry (1985) 0.91
Impotence and diabetes. Histological studies of the autonomic nervous fibers of the corpora cavernosa in impotent diabetic males. Diabetes (1974) 0.91
Relationship of mood disturbance to cigarette smoking status among 252 patients with a current mood disorder. J Clin Psychiatry (2001) 0.91
Hemodialysis in the treatment of psoriasis. A controlled trial. Ann Intern Med (1979) 0.91
Cognitive substrates of thought disorder, II: specifying a candidate cognitive mechanism. Am J Psychiatry (1998) 0.91
Intensity-adaptive segmentation of single-echo T1-weighted magnetic resonance images. Hum Brain Mapp (1997) 0.91
Naloxone administration in obsessive-compulsive disorder: report of two cases. Am J Psychiatry (1983) 0.90
Cerebral glucose metabolism, CSF 5-HIAA levels, and aggressive behavior in rhesus monkeys. Am J Psychiatry (1995) 0.90
Tyramine pressor sensitivity changes during deprenyl treatment. Psychopharmacology (Berl) (1985) 0.90
Description of the Genetic Analysis Workshop 10 bipolar disorder linkage data sets. Genet Epidemiol (1997) 0.89
Abnormalities in the distributed network of sustained attention predict neuroleptic treatment response in schizophrenia. Neuropsychopharmacology (1998) 0.89
Negative association of neuroticism with brain volume ratio in healthy humans. Biol Psychiatry (2001) 0.89
Eye movement task related to frontal lobe functioning in children with attention deficit disorder. J Am Acad Child Adolesc Psychiatry (1994) 0.88